Literature DB >> 10588728

Specific therapy regimes could lead to long-term immunological control of HIV.

D Wodarz1, M A Nowak.   

Abstract

We use mathematical models to study the relationship between HIV and the immune system during the natural course of infection and in the context of different antiviral treatment regimes. The models suggest that an efficient cytotoxic T lymphocyte (CTL) memory response is required to control the virus. We define CTL memory as long-term persistence of CTL precursors in the absence of antigen. Infection and depletion of CD4(+) T helper cells interfere with CTL memory generation, resulting in persistent viral replication and disease progression. We find that antiviral drug therapy during primary infection can enable the development of CTL memory. In chronically infected patients, specific treatment schedules, either including deliberate drug holidays or antigenic boosts of the immune system, can lead to a re-establishment of CTL memory. Whether such treatment regimes would lead to long-term immunologic control deserves investigation under carefully controlled conditions.

Entities:  

Mesh:

Year:  1999        PMID: 10588728      PMCID: PMC24459          DOI: 10.1073/pnas.96.25.14464

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  T lymphocyte responses in HIV-1 infection: implications for vaccine development.

Authors:  C Brander; B D Walker
Journal:  Curr Opin Immunol       Date:  1999-08       Impact factor: 7.486

2.  Control of HIV despite the discontinuation of antiretroviral therapy.

Authors:  J Lisziewicz; E Rosenberg; J Lieberman; H Jessen; L Lopalco; R Siliciano; B Walker; F Lori
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

3.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

4.  Antigenic diversity thresholds and the development of AIDS.

Authors:  M A Nowak; R M Anderson; A R McLean; T F Wolfs; J Goudsmit; R M May
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

Review 5.  Drug resistance in viruses.

Authors:  D D Richman
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

6.  Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.

Authors:  S D Frost; A R McLean
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

7.  Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.

Authors:  S A Kalams; S P Buchbinder; E S Rosenberg; J M Billingsley; D S Colbert; N G Jones; A K Shea; A K Trocha; B D Walker
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

9.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

10.  Antigenic oscillations and shifting immunodominance in HIV-1 infections.

Authors:  M A Nowak; R M May; R E Phillips; S Rowland-Jones; D G Lalloo; S McAdam; P Klenerman; B Köppe; K Sigmund; C R Bangham
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

View more
  26 in total

1.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.

Authors:  Rob J De Boer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

3.  Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.

Authors:  Dominik Wodarz
Journal:  Proc Biol Sci       Date:  2010-02-10       Impact factor: 5.349

4.  Viral dynamics model with CTL immune response incorporating antiretroviral therapy.

Authors:  Yan Wang; Yicang Zhou; Fred Brauer; Jane M Heffernan
Journal:  J Math Biol       Date:  2012-08-29       Impact factor: 2.259

Review 5.  Modeling T cell responses to antigenic challenge.

Authors:  Dominik Wodarz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-01       Impact factor: 2.745

6.  The immunostimulatory and antimicrobial property of two herbal decoctions used in the management of HIV/AIDS in Ghana.

Authors:  George Asumeng Koffuor; Rita Dickson; Stephen Yao Gbedema; Edmund Ekuadzi; Gabriel Dapaah; Lydia Francisca Otoo
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

7.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

8.  Modelling HIV immune response and validation with clinical data.

Authors:  H T Banks; M Davidian; Shuhua Hu; Grace M Kepler; E S Rosenberg
Journal:  J Biol Dyn       Date:  2008-10       Impact factor: 2.179

Review 9.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

10.  Using chemical organization theory for model checking.

Authors:  Christoph Kaleta; Stephan Richter; Peter Dittrich
Journal:  Bioinformatics       Date:  2009-05-25       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.